Sana Biotechnology Inc vs Snowflake Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Snowflake Inc trades at $368.89 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 144.8× Sana Biotechnology Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Snowflake Inc for 54 Days on average.
| SANA | SNOW | |
|---|---|---|
Market Cap | $836.71M | $121.15B |
Volume | 4,507,444 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $5.92 | $368.89 |
52-Week Low | $2.68 | $121.11 |
Typical Hold Time | 23 Days | 54 Days |
Enterprise Value | $749.96M | $121.57B |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $3.63 billion in 2025 but remains unprofitable with a net income margin of -20.07%. Recent positive developments include strategic partnerships with UiPath and a $3.75 billion convertible note offering to fund growth initiatives.
Snowflake presents a growth investment opportunity with strong analyst support (81% buy ratings) and a $418 price target, but faces execution risks from persistent losses and high valuation multiples. The stock's upside depends on continued revenue expansion and path to profitability amid competitive cloud data market pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →